



THE Energy Alliance Group OF NORTH AMERICA



ARCALUX HEALTH RISK MANAGEMENT SYSTEM



Test Overview

Clinical testing of the Arcalux HRMS was conducted by the Aerobiology Laboratory Associates, Inc. of Sterling, Virginia. Testing was conducted to confirm predicted performance by Dr. Wladyslaw Kowalski, the world's foremost authority on airborne pathogens, in terms of UV dose, filter removal rates and overall disinfection or kill rates of pathogenic nosocomial microbes.

Pathogens selected for the trial included MRSA, Serratia Marcescens, Baccillus Atrophaeus and Staphylococcus Aureus. Although not traditional airborne pathogens, they are by far some of the most difficult to control and can become airborne during surface cleaning or the movement of infected material. Test results from these pathogens confirm the systems ability to control all pathogens, whether airborne initially or made airborne from the disturbance of surface contamination, as predicted by Dr. Kowalski.

Testing was conducted in accordance with protocols established by the Environmental Protection Agency (EPA) Office of Research and Development National Homeland Security Research Center for hazardous biological removal. The system was placed in a laboratory room which was injected with mists containing the various organisms. Concentrations used were 800 times greater than the level you would expect to find in a contaminated hospital setting.

Test Results

MRSA was eliminated to 99.7% after the 1st hour and Serratia was eliminated to 100%



CLINICAL TESTING

TYPE: **MRSA**


RESULTS: **99.8% Elimination**



CLINICAL TESTING

TYPE: **Serratia Marcescens**


RESULTS: **100% Elimination**



CLINICAL TESTING

TYPE: **Staphylococcus Aureus**

RESULTS: **99.9% Elimination**



CLINICAL TESTING

TYPE: **Bacillus Atrophaeus**

RESULTS: **99.7% Elimination**